Logo image of ALNA

ALLENA PHARMACEUTICALS INC (ALNA) Stock Fundamental Analysis

NASDAQ:ALNA - Nasdaq - US0181191075 - Common Stock - Currency: USD

0.075  +0 (+3.16%)

After market: 0.0665 -0.01 (-11.33%)

Fundamental Rating

2

ALNA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 559 industry peers in the Biotechnology industry. The financial health of ALNA is average, but there are quite some concerns on its profitability. ALNA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALNA has reported negative net income.
ALNA Yearly Net Income VS EBIT VS OCF VS FCFALNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -10M -20M -30M -40M

1.2 Ratios

Industry RankSector Rank
ROA -243.13%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALNA Yearly ROA, ROE, ROICALNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 -50 -100 -150 -200 -250

1.3 Margins

ALNA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALNA Yearly Profit, Operating, Gross MarginsALNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021

More info and screens

4

2. Health

2.1 Basic Checks

ALNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALNA has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, ALNA has a worse debt to assets ratio.
ALNA Yearly Shares OutstandingALNA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M
ALNA Yearly Total Debt VS Total AssetsALNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

2.2 Solvency

ALNA has an Altman-Z score of -28.08. This is a bad value and indicates that ALNA is not financially healthy and even has some risk of bankruptcy.
ALNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -28.08
ROIC/WACCN/A
WACC10.12%
ALNA Yearly LT Debt VS Equity VS FCFALNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

ALNA has a Current Ratio of 1.58. This is a normal value and indicates that ALNA is financially healthy and should not expect problems in meeting its short term obligations.
A Quick Ratio of 1.58 indicates that ALNA should not have too much problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.58
Quick Ratio 1.58
ALNA Yearly Current Assets VS Current LiabilitesALNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 46.15% over the past year.
EPS 1Y (TTM)46.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ALNA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.22% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y56.68%
EPS Next 2Y25.45%
EPS Next 3Y24.51%
EPS Next 5Y13.22%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALNA Yearly EPS VS EstimatesALNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ALNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALNA Price Earnings VS Forward Price EarningsALNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -0.16
ALNA Per share dataALNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as ALNA's earnings are expected to grow with 24.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.45%
EPS Next 3Y24.51%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALNA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALLENA PHARMACEUTICALS INC

NASDAQ:ALNA (9/7/2022, 8:15:20 PM)

After market: 0.0665 -0.01 (-11.33%)

0.075

+0 (+3.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-15 2022-08-15/amc
Earnings (Next)11-08 2022-11-08
Inst Owners0.23%
Inst Owner Change0%
Ins Owners8.66%
Ins Owner Change0%
Market Cap8.08M
Analysts45.71
Price Target4.08 (5340%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.16
P/tB N/A
EV/EBITDA -0.16
EPS(TTM)-0.49
EYN/A
EPS(NY)-0.31
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.03
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -243.13%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.58
Quick Ratio 1.58
Altman-Z -28.08
F-Score2
WACC10.12%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y56.68%
EPS Next 2Y25.45%
EPS Next 3Y24.51%
EPS Next 5Y13.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A